Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
14.290
Open
14.230
VWAP
13.95
Vol
648.79K
Mkt Cap
749.51M
Low
13.750
Amount
9.05M
EV/EBITDA(TTM)
--
Total Shares
48.55M
EV
874.19M
EV/OCF(TTM)
--
P/S(TTM)
25.06
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
6.88M
-18.77%
-1.089
-19.73%
7.78M
-30.07%
-1.106
-4.71%
13.60M
+492.7%
-1.022
+11.92%
Estimates Revision
The market is revising Upward the revenue expectations for uniQure N.V. (QURE) for FY2025, with the revenue forecasts being adjusted by 4.59% over the past three months. During the same period, the stock price has changed by -12.22%.
Revenue Estimates for FY2025
Revise Upward
+4.59%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+14.18%
In Past 3 Month
Stock Price
Go Down
-12.22%
In Past 3 Month
9 Analyst Rating
161.83% Upside
Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 36.29 USD with a low forecast of 18.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
161.83% Upside
Current: 13.860
Low
18.00
Averages
36.29
High
70.00
161.83% Upside
Current: 13.860
Low
18.00
Averages
36.29
High
70.00
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$70
2025-04-21
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$70
2025-04-21
Reiterates
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$27 → $38
2025-04-01
Reason
Chardan Capital
Daniil Gataulin
Price Target
$27 → $38
2025-04-01
Maintains
Strong Buy
Reason
Chardan took over coverage of uniQure with a Buy rating and price target of $38. The analyst, who cites the potential of the company's AAV-based gene therapy pipeline to "uniquely address" unmet medical need in Huntington's disease, with additional upside potential in epilepsy, ALS, and Fabry disease, believes the shares offer a favorable risk-reward.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$70
2025-03-04
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$70
2025-03-04
Reiterates
Strong Buy
Reason
Wells Fargo
Yanan Zhu
Hold
Maintains
$35 → $30
2025-02-28
Reason
Wells Fargo
Yanan Zhu
Price Target
$35 → $30
2025-02-28
Maintains
Hold
Reason
RBC Capital
Luca Issi
Buy
Reiterates
$24
2025-01-21
Reason
RBC Capital
Luca Issi
Price Target
$24
2025-01-21
Reiterates
Buy
Reason
Mizuho
Uy Ear
Hold
Maintains
$7 → $20
2024-12-19
Reason
Mizuho
Uy Ear
Price Target
$7 → $20
2024-12-19
Maintains
Hold
Reason
Mizuho raised the firm's price target on uniQure to $20 from $7 and keeps a Neutral rating on the shares. The firm cites increased confidence in AMT-130 to obtain accelerated approval in Huntington's disease, given the alignment the company reached with the FDA, for the target increase. The firm, however, has questions about the potential AMT-130 adoption given the complex administration, challenging gene therapy adoption and reimbursement landscape, and competitive development landscape.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Uniqure NV (QURE.O) is -3.36, compared to its 5-year average forward P/E of -8.64. For a more detailed relative valuation and DCF analysis to assess Uniqure NV 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.64
Current PE
-3.36
Overvalued PE
8.78
Undervalued PE
-26.06
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
21.82
Undervalued EV/EBITDA
-21.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
13.22
Current PS
0.00
Overvalued PS
27.59
Undervalued PS
-1.16
Financials
Annual
Quarterly
FY2024Q4
YoY :
-21.95%
5.22M
Total Revenue
FY2024Q4
YoY :
-33.94%
-44.24M
Operating Profit
FY2024Q4
YoY :
+0.08%
-73.26M
Net Income after Tax
FY2024Q4
YoY :
-1.96%
-1.50
EPS - Diluted
FY2024Q4
YoY :
+2.53%
-52.88M
Free Cash Flow
FY2024Q4
YoY :
-374.75%
88.14
Gross Profit Margin - %
FY2024Q4
YoY :
-28.98%
-686.22
FCF Margin - %
FY2024Q4
YoY :
+28.21%
-1.40K
Net Margin - %
FY2024Q4
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
485.7K
USD
4
3-6
Months
2.1M
USD
7
6-9
Months
0.0
USD
0
0-12
Months
161.3K
USD
13
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 223.41% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.6M
Volume
3
6-9
Months
0.0
Volume
0
0-12
Months
150.0K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
6
8.1M
Volume
Months
6-9
1
2.5M
Volume
Months
0-12
2
50.0K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
485.7K
USD
4
3-6
Months
2.1M
USD
7
6-9
Months
0.0
USD
0
0-12
Months
161.3K
USD
13
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
QURE News & Events
Events Timeline
2025-04-21 (ET)
2025-04-21
12:17:11
RBC sees Makary interview as potentially positive for biotech stocks
2025-04-17 (ET)
2025-04-17
07:21:47
uniQure granted Breakthrough Therapy Designation for AMT-130 in Huntington's
2025-01-30 (ET)
2025-01-30
06:42:02
uniQure says IDMC recommends proceeding with dose escalation in AMT-162 trial
Sign Up For More Events
Sign Up For More Events
News
2.0
04-21BenzingaWolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
6.0
04-20Business InsiderAnalysts’ Top Healthcare Picks: Evolent Health (EVH), Gilead Sciences (GILD)
2.0
04-17BenzingauniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Sign Up For More News
People Also Watch
PFIS
Peoples Financial Services Corp
43.710
USD
+1.44%
AGS
PlayAGS Inc
12.110
USD
0.00%
RDVT
Red Violet Inc
39.320
USD
+4.35%
NFBK
Northfield Bancorp Inc
10.550
USD
+3.94%
AIRJ
Montana Technologies Corp
5.070
USD
+1.60%
EVLV
Evolv Technologies Holdings Inc
4.100
USD
-1.44%
NWPX
Northwest Pipe Co
42.880
USD
+1.23%
SVRA
Savara Inc
3.260
USD
+2.19%
RYAM
Rayonier Advanced Materials Inc
4.330
USD
+1.17%
ANGO
AngioDynamics Inc
9.580
USD
+0.63%
FAQ
What is Uniqure NV (QURE) stock price today?
The current price of QURE is 13.86 USD — it has decreased -0.79 % in the last trading day.
What is Uniqure NV (QURE)'s business?
What is the price predicton of QURE Stock?
What is Uniqure NV (QURE)'s revenue for the last quarter?
What is Uniqure NV (QURE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Uniqure NV (QURE)'s fundamentals?
How many employees does Uniqure NV (QURE). have?